219 related articles for article (PubMed ID: 30232698)
21. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
[TBL] [Abstract][Full Text] [Related]
22. The treatment of CML at an environment with limited resources.
Gómez-Almaguer D; Cantú-Rodríguez OG; Gutiérrez-Aguirre CH; Ruiz-Argüelles GJ
Hematology; 2016 Dec; 21(10):576-582. PubMed ID: 27218866
[TBL] [Abstract][Full Text] [Related]
23. Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib.
Ohm L; Lundqvist A; Dickman P; Höglund M; Persson U; Stenke L; Carlsson KS; Björkholm M
Leuk Lymphoma; 2015 May; 56(5):1385-91. PubMed ID: 25139694
[TBL] [Abstract][Full Text] [Related]
24. Assessment of Dasatinib Versus Nilotinib as Upfront Therapy for Chronic Phase of Chronic Myeloid Leukemia in Qatar: A Cost-Effectiveness Analysis.
Adel A; Abushanab D; Hamad A; Abdulla M; Izham M; Yassin M
Cancer Control; 2021; 28():10732748211001796. PubMed ID: 33887995
[TBL] [Abstract][Full Text] [Related]
25. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
26. Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: perspectives from Latin America in the post-tyrosine kinase inhibitor era.
Pasquini MC
Hematology; 2012 Apr; 17 Suppl 1():S79-82. PubMed ID: 22507787
[TBL] [Abstract][Full Text] [Related]
27. Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
Phuar HL; Begley CE; Chan W; Krause TM
Am J Clin Oncol; 2020 Jul; 43(7):517-525. PubMed ID: 32304434
[TBL] [Abstract][Full Text] [Related]
28. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
[TBL] [Abstract][Full Text] [Related]
29. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
30. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
Gambacorti-Passerini C; Piazza R
JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
[No Abstract] [Full Text] [Related]
31. New strategies in controlling drug resistance in chronic myeloid leukemia.
Frame D
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S16-21. PubMed ID: 18056927
[TBL] [Abstract][Full Text] [Related]
32. Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.
Li J; Xu G; Yu S; He L; Guo L
J Int Med Res; 2011; 39(2):337-47. PubMed ID: 21672337
[TBL] [Abstract][Full Text] [Related]
33. Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy.
Efficace F; Stagno F; Iurlo A; Breccia M; Cottone F; Bonifacio M; Abruzzese E; Castagnetti F; Caocci G; Crugnola M; Capodanno I; Martino B; Tiribelli M; Patriarca A; Gozzini A; Pregno P; Saussele S; Cascavilla N; Fozza C; Bergamaschi M; Binotto G; Vignetti M; Rosti G
Leukemia; 2020 Feb; 34(2):488-498. PubMed ID: 31477798
[TBL] [Abstract][Full Text] [Related]
34. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
Taylor MJ; Scuffham PA
Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):117-21. PubMed ID: 19402798
[TBL] [Abstract][Full Text] [Related]
35. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
Lejniece S; Udre I; Rivkina A
Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
[TBL] [Abstract][Full Text] [Related]
37. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis.
Campiotti L; Suter MB; Guasti L; Piazza R; Gambacorti-Passerini C; Grandi AM; Squizzato A
Eur J Cancer; 2017 May; 77():48-56. PubMed ID: 28365527
[TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia.
Kim K; McMillin GA; Bernard PS; Tantravahi S; Walker BS; Schmidt RL
PLoS One; 2019; 14(12):e0226552. PubMed ID: 31869360
[TBL] [Abstract][Full Text] [Related]
39. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
Warren E; Ward S; Gordois A; Scuffham P
Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
[TBL] [Abstract][Full Text] [Related]
40. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]